SCHEMBL6344011

SCHEMBL6344011

CCCS(=O)(=O)NC1CCCCC1(O)c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 2/20 0.39
PSEN2 P49810 2/20 0.39
APH1B Q8WW43 2/20 0.39
NCSTN Q92542 2/20 0.39
APH1A Q96BI3 2/20 0.39
PSENEN Q9NZ42 2/20 0.39
TRPA1 O75762 5/20 0.38
SLC6A3 Q01959 2/20 0.38
ESR1 P03372 1/20 0.38
PGR P06401 1/20 0.38
HTR2A P28223 1/20 0.38
TRPC5 Q9UL62 1/20 0.38
SLC6A4 P31645 1/20 0.37
SLC6A9 P48067 6/20 0.37
OPRM1 P35372 3/20 0.36
OPRL1 P41146 2/20 0.36
SLC6A5 Q9Y345 2/20 0.36
RORC P51449 2/20 0.36
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6345745 0.96 PSEN1 (0.40) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6348751 0.89 PSEN1 (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6353147 0.88 PSEN1 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6345854 0.86 PSEN1 (0.40) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6244914 0.86 SLC6A4 (0.42) SLC6A3SLC6A4SLC6A9OPRM1OPRL1
SCHEMBL6244879 0.85 SLC6A4 (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6240952 0.85 PSEN1 (0.38) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6348964 0.85 PSEN1 (0.41) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6242537 0.84 PSEN1 (0.38) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6239804 0.84 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US disclosed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP disclosed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 PSEN1 340/4885PSEN2 390/4885APH1B 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.